Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017


SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Bayer : buys British developer of treatment for menopausal symptoms

share with twitter share with LinkedIn share with facebook
08/11/2020 | 03:45am EDT
FILE PHOTO: Logo of Bayer AG at a plant of the German pharmaceutical and chemical maker in Wuppertal

Bayer agreed to acquire British biotech firm KaNDy Therapeutics Ltd. for an initial $425 million to strengthen its women's healthcare business with a prospective non-hormonal treatment of menopausal symptoms.

Apart from the $425 million upfront, Bayer agreed to pay further milestone payments of up to $450 million for certain development achievements, with potentially more than $100 million additional sales-dependent milestone payments, the German drugs and pesticides maker said in a statement on Tuesday.

KaNDy recently completed the second of three phases of testing for NT-814, a new non-hormonal daily pill for the relief of hot flushes and night sweats, which Bayer said could generate peak annual sales of more then 1 billion euros ($1.17 billion).

Bayer is seeking to revive its women's healthcare business as sales of birth control pills, with lead brands Yaz and Yasmin, have been dragged lower by cheaper copied versions.

It is close to settling injury claims over inserted birth control device Essure for more than 1 billion euros.

Previous moves to reinvigorate the franchise include an alliance with Germany's Evotec to develop a treatment of polycystic ovary syndrome (PCOS), the most frequent cause of female infertility.

($1 = 0.8527 euros)

By Ludwig Burger

Stocks mentioned in the article
ChangeLast1st jan.
BAYER AG -1.73% 53.47 Delayed Quote.-26.56%
EVOTEC SE -0.05% 22.01 Delayed Quote.-4.51%
share with twitter share with LinkedIn share with facebook
All news about BAYER AG
09/24BAYER : resolves more Roundup cases, judge keeps pause on litigation
09/24BAYER : resolves more Roundup cases, judge keeps pause on litigation
09/21BAYER : opens application window for Grants4Ag
09/18GLOBAL MARKETS LIVE : Tiktok, CaixaBank, Moderna…
09/18Covestro denies it is in takeover talks with Apollo
09/17EXCLUSIVE : In the weeds - How Bayer, U.S. government teamed up against Thailand..
09/17IN THE WEEDS : How Bayer, U.S. govt teamed up against Thailand's glyphosate ban
09/17BAYER : New data reinforce strong clinical profile of Vitrakvi™ for patien..
09/15BAYER : settles thousands of U.S. Roundup cases with trial attorneys
09/15Bayer settles thousands of U.S. Roundup cases with trial attorneys
More news
Sales 2020 43 305 M 50 377 M 50 377 M
Net income 2020 -2 690 M -3 129 M -3 129 M
Net Debt 2020 32 651 M 37 983 M 37 983 M
P/E ratio 2020 -15,9x
Yield 2020 5,31%
Capitalization 52 530 M 61 032 M 61 108 M
EV / Sales 2020 1,97x
EV / Sales 2021 1,89x
Nbr of Employees 101 168
Free-Float 100,0%
Duration : Period :
Bayer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 78,72 €
Last Close Price 53,47 €
Spread / Highest target 106%
Spread / Average Target 47,2%
Spread / Lowest Target -14,0%
EPS Revisions
Werner Baumann Chairman-Management Board
Norbert Winkeljohann Chairman-Supervisory Board
Wolfgang U. Nickl Chief Financial Officer
Bijoy Sagar Chief Information Technology Officer
Paul Achleitner Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG-26.56%61 032
JOHNSON & JOHNSON-0.14%383 497
ROCHE HOLDING AG5.40%304 339
MERCK & CO., INC.-8.82%209 750
PFIZER, INC.-8.73%200 326
NOVARTIS AG-12.61%190 402